« Return to News | CROs/Service Providers

Icon's central labs launches cytometry services

Thursday, May 26, 2011 02:31 PM

The central laboratories arm of Ireland-based global CRO Icon has launched a global cytometry services offering through its facilities in New York, Dublin, Bangalore and Singapore, according to PharmaTimes.

The new service consists of two strands tailored to the particular testing requirements and development phase of a client’s compound.

Clients can work with Icon during the early stages of product development to create compound-specific assays. The Icon Central Laboratories R&D team will collaborate on developing a unique flow cytometry methodology, customized standard operating procedures and other special requirements including reporting, the company said.

These customized flow cytometry panels can then be used throughout the compound development lifecycle.

Icon's second cytometry services offering gives clients the choice of a range of fully validated assays and “is often suited to the large-scale, high-volume requirements of later phase global trials,” the company said.
 
Flow cytometry “has become a preferred testing method for many of our clients, particularly those with autoimmune, oncology and immunodeficiency compounds that require more specialized testing,” said Tom O’Leary, president of Icon Central Laboratories.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.